Skip to content

A study on Siddha Herboââ?¬â??Mineral Medicine "Naaga chendooram"for the Diabetes Neurological complication(Madhumega Avathaigal)

A Randomized control trial on the therapeutic effect of Siddha Herboââ?¬â??Mineral preparation Naaga Chendooram in the treatment of Madhumega Avathai vii - (Diabetic Peripheral Neuropathy)- a complication of Non -Insulin -Dependent (type ii) Dibetes Mellitus. - NCDPN

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/07/035067
Enrollment
80
Registered
2021-07-22
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E114- Type 2 diabetes mellitus with neurological complications

Interventions

Intervention1: NAAGA CHENDOORAM: Dosage:488 Milligrams,Adjuvant:Thirikadhukugu chooranam and honey,Rout of administartion:oral ,Frequency:Twice a day before meal ,Duration of therapy :90 days Control

Sponsors

National Institute of Siddha
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Blood sugar fasting >126 and Postprandial Blood Sugar >200 mg/dl and HbA1c >7% and considered positive for neuropathy total score out of 5 and MNSI Questionnaires . score �7 considered positive for presence of neuropathy total score out of 15.3.Patients who is already under siddha medication for Madhumegam 4.Already diagnosed DM patients with or without clinical symptom.5.symptoms of polyurea,polydipsia ,Nocturia ,Polyphagia ,Body pain ,Weight loss, Tiredness ,Burning feet & palm Genital pruritus Patients who fulfill any of the above four clinical symptoms will be included in the clinical trial.

Exclusion criteria

Exclusion criteria: 1.Blood sugar fasting 200 mg/dl or Postprandial Blood Sugar 350 mg /dl (or) HbA1c 11% 2.IDDM (Insulin Dependent Diabetes Mellitus) Secondary Hypertension ,Secondary Diabetes Mellitus,Coronary double vessel & triple vessel disease Pregnant woman and planning to be pregnant within three months,Lactating mother,Central nervous disorder,Gestational Diabetes Mellitus,Existing renal failure indicated by elevated serum creatinine levels,Subjects those who are not willing to give informed consent

Design outcomes

Primary

MeasureTime frame
Primary outcome is assessed by comparing the blood sugar ,HbA1c level and diabetic peripheral neuropathy in pre and post treatment.Timepoint: 90 days

Secondary

MeasureTime frame
The secondary outcome will be elucidate through study the In Vitro anti diabetic activity and mechanism of action of Naaga chendooram in alpha ââ?¬â??amylase inhibition assay and alpha glucosidase inhibition assay and The co-factors such as food habits, body constitution in Madhumegam, weight , height, Body mass index, occupation, income, socio-economic status etc will be studiedTimepoint: 90 days

Countries

India

Contacts

Public ContactDr K VIGNESH KUMAR

National Institute of Siddha

drlakshmiramaswamy@gmail.com9025575185

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026